rodney-320x320
February 13, 2014 - CBC News - The Atlantic Cancer Research Institute has developed a cancer-detecting test that could be done in a doctor's office using a small sample of bodily fluid, such as saliva or urine, instead of a biopsy.

* Article published by CBC News on Feb 13, 2014

logo neplogo institut
December 3, 2013
- New England Peptide (NEP), a Massachusetts based biotech manufacturer, and The Atlantic Cancer Research Institute (ACRI), a leading cancer research center in Atlantic Canada, have launched a new biotech company. Excipio Technologies Inc. has a mandate to commercialize the Vn96 peptide developed by both NEP and ACRI for the isolation of exosomes and extracellular microvesicles.

Excipio

John Betts, MLA Moncton-Cresent
Honourable Marie-Claude Blais, Minister of Education and Early Childhood Development and Minister responsible of Women's equality
Rodney Ouellette, M.D., Ph.D, President and Scientific Director, ACRI
Sam Massoni, President, New England Peptide
NB Premier, Honourable David Alward
Doug Robertson, President and Chief Executive Officer, Venn

November 8, 2013
– The Atlantic Cancer Research Institute (ACRI), a leading cancer research centre in Atlantic Canada, and New England Peptide (NEP), a Boston based biotech manufacturer, have launched a new company to be based in Moncton, NB. Excipio Technologies Inc. has a mandate to commercialize the Vn96 peptide developed by both ACRI and NEP.

Image ME kit June 12 2013
July 25, 2011
- New England Peptide (NEP) and the Atlantic Cancer Research Institute (ACRI) announced today that they have jointly submitted a patent application for cancer-related peptide reagents which have the potential to deliver breakthroughs in cancer diagnostics and more individualized therapies for cancer patients.

Excipio Technologies Inc.

35 Providence Street
Moncton, New Brunswick
E1C 8X3
Canada
info@excipio.ca

METM Kit product information:
sales@newenglandpeptide.com

Business Development Contact:
Remi Richard
Business Development Agent
remi.richard@canceratl.ca
Phone : +1 506 869 2048
Fax : +1 506 862 7571

Unlock the diagnostic potential of exosomes

Increase the specificity and sensitivity of your biofluid-based molecular diagnostic assays with Vn96. The Vn96 platform technology can give you access to improved clinical diagnostics directly on site or at point-of-care with faster, more specific and efficient exosome isolation. All while using your existing infrastructure, minimizing your isolation time to less than an hour and eliminating the need for ultracentrifugation or expensive antibodies and filtration methods.
logo iarc logo nep

Follow us

icon facebook off icon linkedin off icon youtube off icon google off icon twitter off